Abstract

**Background:** The direct agglutination test (DAT) has proved to be a very important serodiagnostic tool combining high levels of intrinsic validity and ease of performance. Otherwise, fast agglutination screening test (FAST) utilises only one serum dilution making the test very suitable for the screening of large populations.

**Results:** We have tested FAST and DAT for the detection anti-*Leishmania* antibodies in serum samples from patients with American visceral (AVL) and cutaneous leishmaniasis (ACL) in Minas Gerais State, Brazil. The DAT on serum and blood samples of confirmed AVL patients found all samples positive at a serum dilution of \( \geq 1:800 \). This dilution was subsequently used as cut off value in the study. The blood and serum samples of these confirmed patients could also be clearly read in FAST using a 1:100 dilution with the same high sensitivity. DAT and FAST were not able to detect significant amounts of antibodies in samples from ACL patients and are not suitable for the diagnosis of this manifestation of the disease.

**Conclusion:** We suggest that both DAT and FAST are very practical diagnostic tools for the serodiagnosis of AVL under rural conditions as both serological tests do not require sophisticated equipment, a cold chain and are very simple to perform.

**Background**

American visceral leishmaniasis (AVL) a protozoan disease caused by *Leishmania chagasi* parasites, constitutes a major health problem in Brazil. In the last few years the number of human cases of AVL in the metropolitan region of Belo Horizonte (MRBH), state of Minas Gerais, Brazil has increased, indicating an elevation in the transmission rate of the disease [1]. Dogs and fox are considered to be the main reservoirs host for this parasite [2,3]. The diagnosis of AVL is based on clinical-epidemiological characteristics, by microscopical demonstration of the parasite in biopsies of aspirates, indirectly by serological tests and culturing or molecular methods like the polymerase chain reaction (PCR) [4-6]. Several
techniques can be used for the sero-diagnosis of AVL. The indirect fluorescence technique (IFAT) was the technique of choice until 1974 [7,8]. Since then counter-current immuno-electrophoresis and enzyme-linked immunosorbent assay (ELISA) have been found to be powerful tools for the sero-diagnosis of leishmaniasis [9]. In addition, several other serological tests have been developed. The direct agglutination test (DAT) has proved to be a very important sero-diagnostic tool combining high levels of intrinsic validity and ease of performance [10-12]. The test uses whole, stained promastigotes either as a suspension or in a freeze-dried form [10,11,13,14]. By using the freeze-dried antigen, logistic problems, such as the need of a cold chain for storage of antigen, are avoided, making the DAT very suitable for use under field conditions.

Although the direct agglutination test (DAT) for the sero-diagnosis of visceral leishmaniasis has a high sensitivity and specificity [6,13,14], it still has some limitations like the relative long incubation time (18 h) and the need for serial dilutions of blood or serum. In order to circumvent these problems Schoone et al. [15] developed a fast agglutination-screening test (FAST) for the rapid detection of anti-Leishmania antibodies in serum samples and in blood collected on filter paper. The FAST utilises only one serum dilution (qualitative result) and requires 3 hours of incubation. This makes the test very suitable for the screening of large populations.

The increasing importance of AVL in man and its high rates of lethality in the Metropolitan Region of Belo Horizonte (MRBH) indicate that a rapid and relatively simple method is needed for the routine diagnosis of this disease. The objective of this study was to evaluate DAT and FAST as potential AVL diagnostic methods using clinical samples from this region in Brazil.

**Materials and methods**

**Serum samples**

This study was carried out utilising serum samples from different patient groups from a metropolitan region of Belo Horizonte (MRBH), Minas Gerais State and some control samples from other regions (see below). Samples and information of patients (age, sex, symptomatology, clinical, address) were sent to the laboratory through the existing health care system of MRBH, Minas Gerais, Brazil. Written consent was obtained from the patient or their relative for this study.

The following groups of samples were included in the present study:

1. Serum samples of AVL patients parasitologically confirmed (microscopical examination from bone marrow aspirate smears) (n = 16).
2. Serum samples of patients clinically suspected of AVL (fever, spleen enlargement, pallor, weight loss), but not parasitologically confirmed (n = 99).
3. Serum samples of patients presenting with active cutaneous leishmaniasis lesions (n = 85).
4. Serum samples of patients with confirmed Chagas’ disease (n = 12)
5. Serum samples of patients (Uganda) with confirmed African trypanosomiasis (n = 5)
6. Serum samples of patients (Kenya) with confirmed *P. falciparum* malaria (n = 5)
7. Serum samples of confirmed toxoplasmosis patients (The Netherlands) (n = 5)
8. Serum samples of apparently healthy individuals from an AVL endemic region in Brazil (n = 19)
9. Serum samples of healthy blood donors from a non-endemic region (The Netherlands; n = 5)

**Serology**

The presence of *Leishmania* antibodies in all the serum samples was determined by FAST and DAT. A sub-set of the samples (groups 1 – 3) were also analysed with IFAT. Antigen for FAST and DAT were prepared as described earlier [13,15]. The FAST was performed according to the protocol described previously [15]. In brief, serum samples were diluted 1:100 in physiological saline (NaCl 0.85%) to which 0.78% β–mercaptopoethanol was added in a V-shaped microtitre plate (Greiner, Germany). Next, 20 µl of this 1:100 dilution was transferred to another well of the V-shaped microtitre plate and 20 µl FAST antigen (2 × 10^6 promastigotes/ml) was added. The plate was carefully shaken, covered with a lid and allowed to incubate for 3 hours at room temperature after which the results were read. Appropriate positive and negative controls were always included on each plate.

The DAT was performed essentially as previously described by [10,13]. In brief, the samples were diluted in physiological saline (0.9% NaCl) containing 0.78% β– mercaptoethanol. Two-fold dilution series of the sera were made in a V-shaped microtitre plate, starting at a dilution of 1:100 (step 1) and going up to a maximum serum dilution of 1:102,400 (step 11). Wells 12 was used as a negative control. Fifty µl DAT antigen (concentration of 5 × 10^7 parasites per ml) was added to each well containing 50 µl diluted serum and the results were read after 18 hours of incubation. The cut-off value of the DAT was set at >1:800.
The IFAT was, due to logistic problems, only performed on a selection of the serum samples using a commercial kit for the diagnosis of human leishmaniasis (Fiocruz/Bio-Manguinhos, Rio de Janeiro, Brazil). IFAT was performed according to the instructions of the manufacturer for detection of antibodies in serum diluted from 1:40 up to 1:640.

**Statistical analysis**

The sensitivity and specificity of the DAT and FAST in the present study were calculated as follows: Sensitivity = TP/(TP+FN) × 100% and Specificity = TN/(TN+FP) × 100%. Where TN represents true negative, TP true positive, FN false negative and FP false positive. The sensitivity of the two tests, FAST and DAT, was assessed with sera from confirmed AVL patients (n = 16). Sera of healthy controls (n = 24) and sera of patients with confirmed other diseases (n = 112) were used to determine the specificity of DAT and FAST.

The degree of agreement between FAST, DAT and IFAT was determined by calculating Kappa (κ) values with 95% confidence intervals using Epi-info version 6. Kappa values express the agreement beyond change and a κ value of 0.21 – 0.60 represents a fair to moderate agreement, a κ value of 0.60 – 0.80 represents a substantial agreement and a κ>0.80 represents almost perfect agreement beyond change [16]. The calculation of the degree of agreement between DAT and FAST was based on all serum samples, whereas the κ values for DAT-IFAT and FAST-IFAT were only based on the results obtained with the confirmed and suspected AVL serum samples.

**Results**

The results of the serological analysis with DAT and FAST are presented in Tables 1 and 2, respectively. The sensitivity of the DAT in the present study was calculated to be 100% and its specificity 97.8% (3 false positive results).

The FAST had a sensitivity of 100% and a specificity of 92.5% (11 false positive results). The results of the IFAT testing are presented in Table 3. The sensitivity and specificity of the IFAT could not be adequately calculated as a sufficient number of negative samples was not analysed with this test. It should be noted that IFAT tested 1 confirmed AVL patient negative and 7 patients only had a low IFAT titre. In contrast, IFAT found about 50% of all confirmed ACL patients sero-positive, whereas neither DAT nor FAST was able to detect antibodies in these serum samples. The DAT found 77 out of 99 samples of patients suspected (but not parasitologically confirmed) of AVL positive. It was observed that 79/99 patients were FAST positive and 84/99 patients were IFAT positive with serum dilutions varying from 1:40 to 1:640.

A high degree of agreement (96%) was observed between FAST and DAT (Table 4a). The agreement beyond change (κ value) was 0.92. In addition, substantial agreement was observed between DAT and IFAT (93%; Table 4b) or FAST and IFAT (94%; Table Table 4c), with κ values of 0.75 and 0.80, respectively.

**Discussion**

In view of the public health importance of AVL and the inherent difficulties of conventional diagnosis techniques, we evaluated in the present study the performance of the sero-diagnostic tests, DAT and FAST. Both test displayed a very high sensitivity and specificity corroborating with previous studies [10,13-15]. It is noted that the sensitivity of DAT and FAST observed in the present study was determined using a relatively low number of confirmed patients, and therefore 100% sensitivity is not claimed.

The antigen on which DAT and FAST are based is a strain of *L. donovani*, whereas human and canine visceral leishmaniasis in Brazil is caused by *Leishmania chagasi*, both species belonging to the *L. donovani* complex. Apparently
the use of an heterologous antigen did not affect the performance of both tests for the detection of anti-\textit{Leishmania} antibodies in Brazilian AVL patients. The DAT found all parasitologically confirmed AVL patients positive at a serum dilution of $\geq 1:800$, which was subsequently used as the cut off dilution in the present study. This serum dilution is comparable to the cut off dilutions found in several other studies [13,14]. The FAST also found all confirmed cases positive, which should be the case as this test is intended as a screening test that should not miss any AVL patient. This result is even better than a previous evaluation of the FAST in which some cases were missed [15].

We have also compared the performance of IFAT with DAT and FAST on serum samples of confirmed AVL cases and suspects. The IFAT missed one confirmed patient that had a very high DAT serum dilution. On the other hand, IFAT found slightly more suspected ALV patients positive (84/99) than DAT (77/99) or FAST (79/99) did. However, there was in general a very good agreement between the

Table 2: Fast agglutination screening test (FAST) results for anti-\textit{Leishmania} antibodies in various patients groups.

| Patient group                  | FAST negative | Fast Positive | Total (n) |
|-------------------------------|---------------|---------------|-----------|
| 1 – Confirmed AVL             | 0             | 16            | 16        |
| 2 – Suspected AVL             | 20            | 79            | 99        |
| 3 – Confirmed CL              | 82            | 3             | 85        |
| 4 – Confirmed Chagas’ disease | 6             | 6             | 12        |
| 5 – Confirmed trypanosomiasis | 4             | 1             | 5         |
| 6 – Confirmed malaria         | 5             | 0             | 5         |
| 7 – Confirmed toxoplasmosis   | 5             | 0             | 5         |
| 8 – Healthy endemic controls  | 18            | 1             | 19        |
| 9 – Healthy non-endemic controls | 5            | 0             | 5         |

Table 3: Indirect Immunofluorescence Test (IFAT) results for anti-\textit{Leishmania} antibodies in serum of sub-set of the different patients groups (NR = no reaction).

| Patient group                  | NR | 1:40 | 1:80 | 1:160 | 1:320 | 1:640 | Positive/Total (n) |
|-------------------------------|----|------|------|-------|-------|-------|-------------------|
| 1 – Confirmed AVL             | 1  | 1    | 6    | -     | 6     | 2     | 15/16             |
| 2 – Suspected AVL             | 15 | 7    | 20   | 20    | 23    | 14    | 84/99             |
| 3 – Confirmed ACL             | 37 | 3    | 23   | 12    | 9     | 1     | 48/85             |

Table 4: Comparison between DAT, FAST and IFAT using serum samples from suspected visceral leishmaniasis patients from the Belo Horizonte Metropolitan Region.

A. Comparison between DAT and FAST

|                  | FAST + | FAST - | Total |
|------------------|--------|--------|-------|
| DAT +            | 96     | 0      | 96    |
| DAT -            | 10     | 145    | 155   |
| Total            | 106    | 145    | 251   |

Comparison between DAT and IFAT

|                  | IFAT + | IFAT - | Total |
|------------------|--------|--------|-------|
| DAT +            | 92     | 1      | 93    |
| DAT -            | 7      | 15     | 22    |
| Total            | 99     | 16     | 115   |

C. Comparison between FAST and IFAT

|                  | IFAT + | IFAT - | Total |
|------------------|--------|--------|-------|
| FAST +           | 94     | 1      | 95    |
| FAST -           | 5      | 15     | 20    |
| Total            | 99     | 16     | 115   |
performance of the three tests with regard to the sea-diagnosis of AVL. In contrast, both FAST and DAT found only a very limited number of ACL cases sero-positive. IFAT found approximately 50% of these cases positive, albeit with generally very low serum titres. DAT and FAST based on L. donovani antigen are not suitable for the sero-diagnosis of ACL [13].

Conclusion
As final remarks, we can conclude that DAT and FAST are very suitable tools for the sero-diagnosis of AVL. Both tests are easy to interpret, as well as being specific and sensitive. The DAT is very practical under field or rural conditions, as no specialised equipment is required nor a cold chain is necessary for the storage of antigen. In addition, the FAST requires only one serum dilution and the results can be read within 3 hours. The FAST can be used to screen large populations, for example in situations such as epidemics where large number of suspects are seen at the clinic or cases where immediate treatment is necessary.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
Silva ES performed the practical work as part of his PhD study, partly in Brazil and partly in the Netherlands, wrote the concept of the paper. Schoone GJ research technician performed part of the sample and data analysis, produced DAT and FAST antigen and invented the FAST test. Gonijo CMF took part in the study design, supervised practical work in Brazil and assisted in writing the concept of the paper. Pacheco RS and Brazil RP former supervisors of Silva ES took part in study design. Schallig HDFH supervised the practical work in the Netherlands, data analysis, final preparation of manuscript, corresponding author

Acknowledgements
This study was supported by a grant from the Hubrecht-Janssen Foundation (Amsterdam, The Netherlands). This investigation received financial support from the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), grant 10245 from Director’s Initiative Fund.

References
1. Silva ES, Gontijo CMF, Pacheco RS, Fiúza VO, Brazil RP. Visceral leishmaniasis in the Metropolitan Region of Belo Horizonte, State of Minas Gerais, Brazil. Mem Inst Oswaldo Cruz 2001, 96:285-291.
2. Deane LM, Deane MP. Visceral leishmaniasis in Brazil: geographical distribution and transmission. Rev Inst Med Trop São Paulo 1962, 4:198-212.
3. Silva ES, Pirmez C, Gontijo CMF, Fernandes O, Brazil RP. Visceral leishmaniasis in the crab-eating fox (Cerdocyon thous) in south-east Brazil. The Vet Rec 2000, 147:421-422.
4. Mathis A, Deplazes P. PCR, in vitro cultivation for detection of Leishmania spp. In diagnostic samples from human and dogs. J Clin Microbiol 1995, 33:1145-1149.
5. Silva ES, Pacheco RS, Gontijo CMF, Carvalho IR, Brazil RP. Visceral leishmaniasis caused by Leishmania (Viannia) braziliensis in a patient infected with human immunodeficiency virus. Rev do Inst Med Trop São Paulo 2002, 44:145-149.
6. Schallig HDFH, Oskam L. Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification. Trop Med Intern Health 2002, 7:641-651.
7. Camargo ME, Rebonato C. Cross-reactivity in immunofluorescence for Trypanosoma and Leishmania antibodies. Am J Trop Med Hyg 1969, 18:500-505.
8. Zuckerman A. Current status of the immunology of blood and tissue Protozoa. I. Leishmania. Exp Parasitol 1975, 38:370-400.
9. Mukerji K, Roy S, Mukhopadhyay P, Gupta PK, Ghosh DK: Evaluation of different subcellular fractions of Leishmania donovani antigen for immunodiagnosis of visceral leishmaniasis. Indian J Exp Biol 1984, 22:120-122.
10. Harith AE, Kolk AHJ, Leuwenburg J, Muigai R, Hügfii E, Jelsma T, Kager A: Improvement of a direct agglutination test for field studies of visceral leishmaniasis. J Clin Microbiol 1988, 26:1321-1325.
11. Zijlstra EE, Osman OF, Hofland HWC, Oskam L, Ghalib HW, EI-Hassan AM, Kager PA, Meredith SEO: The direct agglutination test for diagnosis of visceral leishmaniasis under field conditions in Sudan: comparison of aqueous and freeze-dried antigens. Trans R Soc Trop Med Hyg 1997, 91:671-673.
12. Boelaert M, El Sali S, Jacques D, de Muyncik A, van der Stuyft P, Le Ray D: Operational validation of the Direct Agglutination Test for diagnosis of visceral leishmaniasis. Am J Trop Med Hyg 1999, 60:129-134.
13. Meredith SEO, Kroon NCM, Sondorp E, Seaman J, Goris MGA, van Ingen CW, Oosting H, Schoone GJ, Terpstra WJ, Oskam L: Leish Kit, a stable direct agglutination test based on freeze-dried antigen for the serodiagnosis of visceral leishmaniasis. J Clin Microbiol 1995, 33:1742-1745.
14. Oskam L, Nieuwenhuys JL, Hailu A: Evaluation of the direct agglutination test (DAT) using freeze dried antigen for the detection of anti-Leishmania antibodies in stored sera from various patients groups in Ethiopia. Trans R Soc Trop Med Hyg 1999, 93:275-277.
15. Schoone GJ, Hailu A, Kroon CCM, Nieuwenhuys JL, Schallig HDFH, Oskam L: A fast agglutination test (FAST) for the detection of anti-Leishmania antibodies. Trans R Soc Trop Med Hyg 2001, 95:400-401.
16. Altman DG: Practical Statistics for Medical Research. Volume 1. Chapman & Hall, London, U.K.; 2001:-.